Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RV 568

Next Previous
Drug Profile

RV 568

Alternative Names: JNJ 49095397; RV-568

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RespiVert
  • Developer Janssen Biotech; RespiVert
  • Class Antiasthmatics; Antibronchitics; Antihistamines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Lung disorders; Seasonal allergic rhinitis

Most Recent Events

  • 22 Jul 2015 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation,Aerosol)
  • 01 Sep 2014 Janssen Research & Development completes a phase II trial for Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (inhalation) (NCT01867762)
  • 01 Sep 2013 Phase-II clinical trials in Chronic obstructive pulmonary disease in Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Russia, Romania, USA and United Kingdom (Inhalation) after September 2013
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top